LATITUDE-TIMI 60

LATITUDE-TIMI 60 assessed whether losmapimod can safely reduce the risk of a subsequent cardiovascular event when started immediately after ACS.

MAIN RESULTS:
Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial

JAMA. 2016 Apr 19;315(15):1591-9.

PRESENTATIONS

TIMI 60 Slides

OTHER PUBLICATIONS

Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial. Am Heart J. 2015 May;169(5):622-630.e6.

Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. J Am Coll Cardiol. 2019 Dec 17;74(24):3013-3022.

Inhibition of p38 MAP Kinase in Patients with ST-Elevation Myocardial Infarction – Findings from the LATITUDE TIMI 60 Trial. Am Heart J. 2022 Jan;243:147-157.

Biomarkers in the IL-6 Pathway and Cardiovascular Outcomes in Patients With STEMI in LATITUDE-TIMI 60. JACC Adv. 2024 Feb 22;3(4):100866.